Nebenwirkungen · Brinavess
BRINAVESS 20 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-123179 · Präparat HOS-095653
Atrial flutter Atrial fibrillation patients receiving vernakalant have a higher incidence of converting to atrial flutter within the first 2 hours post-dose (1.2 % versus 0 % in placebo). With continuation of the infusion as recommended above, the majority of these patients continue to convert to sinus rhythm. In the remaining patients, electrical cardioversion can be recommended. In clinical studies to date, patients who developed atrial flutter following treatment with vernakalant did not develop 1:1 atrioventricular conduction. However, in post-marketing experience rare cases of atrial flutter with 1:1 atrioventricular conduction are observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T12:45:00Z · SHA-256 051045e04093fc1285e5944538bcef986071caea205fe960937fd6a5f38d9a56 · Passage b9a221046be4e65e2858788dbdd542eb0acf5542e415c610e33046b910046d1b · Zeichen 4102–4756 im Abschnitt